The U.S. Food and Drug Administration (FDA) has approved the combination of Merck’s KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) for the adjuvant treatment of adult patients with clear cell renal cell carcinoma (ccRCC) at intermediate-high or high risk of recurrence. This regulatory milestone marks the first time a PD-1 inhibitor and a HIF-2α inhibitor have been approved for use together, according to a statement from Merck.
How does the KEYTRUDA and WELIREG combination work?
The treatment targets cancer recurrence through two distinct biological pathways. According to Merck, KEYTRUDA is an anti-PD-1 therapy that helps the immune system detect and attack tumor cells. WELIREG, a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, works by blocking the interaction between HIF-2α and HIF-1β. This mechanism disrupts pathways that tumors use to thrive in low-oxygen environments, potentially hindering cellular proliferation and angiogenesis.
Clear cell renal cell carcinoma accounts for approximately 70% of all renal cell carcinoma diagnoses, making it the most common subtype of kidney cancer globally.
What were the results of the LITESPARK-022 trial?
The FDA approval stems from the Phase 3 LITESPARK-022 trial, which evaluated 1,841 patients. Data reported by Merck show that the combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence, metastasis, or death by 28% compared to KEYTRUDA plus a placebo. The estimated 24-month disease-free survival rate was 81% for the combination arm, compared to 74% for those receiving KEYTRUDA monotherapy. Dr. Toni K. Choueiri of the Dana-Farber Cancer Institute noted that these results provide a new option for patients to help prevent the return of ccRCC after surgery.
What are the primary safety considerations for patients?
Treatment with this combination carries significant risks. According to the prescribing information provided by Merck, WELIREG carries a boxed warning regarding embryo-fetal toxicity; healthcare providers must verify pregnancy status before starting the drug. Additionally, clinicians must monitor patients for severe anemia and hypoxia, which are known side effects. In the LITESPARK-022 study, serious adverse reactions occurred in 30% of patients receiving the combination, with pneumonia, hypoxia, and pneumonitis reported as the most frequent serious events.
Patients should report any symptoms of hypoxia—such as shortness of breath or decreased oxygen saturation—to their oncology team immediately, as early intervention can help manage the severity of these reactions.
Future trends in renal cell carcinoma treatment
The shift toward combining immunotherapies with novel targeted agents like HIF-2α inhibitors signals a broader trend in oncology. Industry data from Merck indicates that the company is currently evaluating more than 30 registrational studies across various cancer types to explore earlier intervention. By moving treatments into the adjuvant setting—the period following primary surgery—researchers aim to eliminate microscopic disease before it manifests as metastatic cancer. This approach contrasts with traditional models that often focused on advanced-stage disease, reflecting a strategic pivot toward potentially curative, early-stage management.
Frequently Asked Questions
- Who is eligible for the new KEYTRUDA and WELIREG combination?
It is approved for adult patients with ccRCC who are at intermediate-high or high risk of recurrence after a nephrectomy or resection of metastatic lesions. - How is KEYTRUDA administered in this regimen?
KEYTRUDA is administered intravenously, while KEYTRUDA QLEX is available as a subcutaneous injection. Patients should consult their oncologist for the specific dosing schedule. - Can this treatment be used during pregnancy?
No. According to Merck, exposure to WELIREG during pregnancy can cause embryo-fetal harm, and effective non-hormonal contraception is required. - Where can patients find financial assistance?
The Merck Access Program provides reimbursement support and co-pay assistance for eligible patients. You can contact them at 855-257-3932.
Are you or a loved one navigating a kidney cancer diagnosis? Understanding your treatment options is the first step toward informed care. Leave a comment below with your questions or subscribe to our newsletter for the latest updates in oncology research.
Worth a look